Carregant...
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma
Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) kinase, a protein that has been shown to be particularly active in metastatic renal cell carcinoma (mRCC) with poor prognosis. Therefore, temsirolimus should be considered as the first-line treatment indicated in mRCC patients...
Guardat en:
| Publicat a: | Ther Adv Urol |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4485412/ https://ncbi.nlm.nih.gov/pubmed/26161146 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287215574457 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|